Abstract Thermal spray coatings have been commonly applied on medical devices for various reasons, e.g., surface roughening, biological fixation, and similarity of chemical composition to bone minerals. Generally, to introduce a thermal spray-coated device to the US market, a premarket review of the coated device is necessary by the US Food and Drug Administration (FDA). This article aims to improve understanding regarding FDA review of thermal spray coatings in orthopedic medical device marketing applications and expectations for information to be submitted as part of this process. While different thermal spray technologies and materials have been used for coatings on medical devices, thermal spray coatings often seen by the FDA on orthopedic devices include plasma-sprayed titanium (Ti) coatings and hydroxyapatite (HA) coatings as well as Ti/HA dual coatings. The coated devices are mostly metals (e.g., Ti alloy, cobalt-chromium alloy, stainless steel alloys) and some polymers (e.g., polyetheretherketone). The FDA does not clear or approve individual coatings or materials; rather, coatings and materials are evaluated as part of the final, finished medical device in the context of the specific device technological characteristics and intended use. The FDA has two current guidance documents for orthopedic implants with modified metallic surfaces and hydroxyapatite coatings, which outline the FDA's recommendations for full characterization and testing of these two types of coatings, respectively. Additionally, the standards organizations (e.g., ISO and ASTM) have developed many materials and testing standards for these coatings, some of which are recognized by the FDA. It is helpful that the coating companies reference these standards for appropriate material/coating specifications, testing methods, and acceptance criteria. Depending on the intended use of the coated device, it is important that coating properties also address some items specific to that device type. Additionally, the impact of cleaning, sterilization, and packaging/shelf-life processes on the coating properties is also considered to ensure that the coated device is safe for its intended use.
Introduction
Coatings have been applied on the surface of numerous medical devices to achieve various physical, chemical, microstructural, and mechanical properties, and as a result, anticipated clinical effects (Ref 1). In the USA, to introduce certain new medical devices to the market, a marketing application to the US Food and Drug Administration (FDA) is required to demonstrate that the device is as safe and effective as a predicate device or has a reasonable assurance safety and effectiveness for its intended use. Depending on the classification of the medical device, different types of marketing applications will be required (Ref 2). For a medical device containing a surface coating, inadequate coating integrity could lead to device failure and clinical complications such as poor fixation and particulate generation. Therefore, materials characterization, some manufacturing details, and testing data regarding the coating are important to include as part of the marketing application and will be reviewed by the FDA to support the substantial equivalence or safety and effectiveness of the coated medical device.
Among various coating technologies (Ref 1), thermal spraying is one of the most commonly used and wellestablished techniques for coating medical devices and its major applications are within orthopedic and dental devices . This article aims to help the thermal spray community to have a better understanding of the FDA premarket review process of thermal spray coatings on orthopedic medical devices, and the information that is important to submit in a marketing application as part of this process. As most thermal spray-coated orthopedic devices are cleared through a Premarket Notification (510(k)) process or approved through a Premarket Approval (PMA) process, this article will focus on the review of these two types of marketing applications. The important information generally includes a description of the thermal spray process and full characterization of the thermal spray coatings including their physicochemical, microstructure, and mechanical properties, as well as their effect on the substrate (i.e., implant) materials. The information can be provided as a part of a marketing application, or can be provided in a Medical Device Master File (MAF) from the coating company, which can be referenced by multiple device manufacturers to support their marketing applications. The article is not intended to address the clinical concerns of thermal spray coatings on medical devices or to discuss all thermal spray coatings using various technologies and/or applied on different medical devices. Instead, it will focus on plasma spray coatings on orthopedic devices as these are the most commonly seen thermal spray coatings by the FDA, and therefore will be used as an example to illustrate the FDA review process of these coatings in a marketing application. It should be noted that this article is intended to illustrate FDA review processes for the thermal spray community, and has no intent to be used in place of FDA guidance documents.
Plasma Spray Coatings on Orthopedic Devices
Plasma spray coatings have been applied on the surface of orthopedic devices for several reasons, such as surface roughening, biological fixation and similarity of chemical composition to bone minerals (Ref 5, 6) . Most of these coatings are applied on the bone-contacting surface of the devices (or ''implants''; these terms will be used interchangeably hereafter in this article), and this article will discuss the plasma spray coatings that are intended for bone contacting only. Table 1 summarizes the most commonly seen plasma spray coatings on orthopedic devices in terms of coating types and materials, plasma spray techniques, device type and substrate material, and whether the device is labeled as porous coated for biological fixation.
Design of coatings: The plasma spray coating can be designed to have different physical layers (e.g., a Ti coating with a dense base layer and a porous surface layer), surface roughness, and microstructure (e.g., thickness, porosity, pore size, and interconnecting pores). Depending on the microstructure of the coating, some of the Ti coatings and Ti/HA coatings are designed to be porous for biological fixation and therefore need to address additional items outlined by FDA guidance, which will be further discussed in ''How to Prepare Your Coating Information for FDA Review'' section, below.
Application of coatings on orthopedic devices: As noted in the Table 1 , some of the listed devices (e.g., joint arthroplasties) are a system of multiple components and the coating can be applied on one or more components in the system. For example, a typical total hip system consists of an acetabular shell, acetabular liner, a femoral head, a femoral stem, and sometimes optional accessories. The same or different coatings can be applied on the surface of the femoral stem, the acetabular shell or both. Additionally, the coating can be applied on different portions of the implants, such as the proximal portion of a hip stem or both the proximal and distal portions of a hip stem. The coatings on some specific devices require additional information for that device type, which will be further discussed in ''How to Prepare Your Coating Information for FDA Review'' section. Some photographs of these coated devices are shown in Fig. 1 for illustration only.
Marketing Applications for Medical Devices
To introduce certain new medical devices to the US market, a marketing application demonstrating substantial equivalence to a predicate (a legally marketed device to which substantial equivalence is drawn in a 510(k)) or a reasonable assurance of safety and effectiveness of the medical device should be submitted to the FDA for review. Medical devices are categorized into one of three classes, based on the degree of risk they present, including (Ref 2):
• Class I-lowest risk: Class I devices are subject to general controls.
• Class II-moderate risk: Class II devices are subject to general controls and special controls. • Class III-highest risk: Class III devices are subject to general controls and premarket approval.
Once the device classification is determined, a marketing application should be selected for that device. Table 2 summarizes the common types of marketing applications (Ref 2) . Depending on the type of marketing application, the device will be reviewed accordingly to ensure that the device is safe and effective for its intended use before it can be marketed and sold in the USA. Note that from a regulatory perspective, the terms ''cleared'' (for 510(k)s), ''approved'' (for PMAs and HDEs), and ''granted'' (for De Novos) have different regulatory implications.
Please see the following FDA website for a detailed description of the general controls, special controls, classification, and the four types of marketing applications: https://www.fda.gov/MedicalDevices/DeviceRegulation andGuidance/Overview/GeneralandSpecialControls/ucm200 5378.htm (Ref 12) .
The plasma spray-coated orthopedic devices listed in Table 1 are Class II or Class III devices and are primarily submitted to the FDA as 510(k)s or PMAs. Note that the device classification is based on the degree of risk they present as discussed in the beginning of this section, and addition of a surface coating on a device does not necessarily increase or decrease the degree of risk for the device. As indicated in ''Plasma Spray Coatings on Orthopedic Devices'' section above, some of the coated devices (e.g., joint arthroplasties) are a system of multiple components, and the device classification is based on the level of risk of the system, not on a single component or feature (e.g., surface coating). Depending on the intended use and technology of the device, a plasma spray-coated orthopedic device can also be submitted as an Evaluation of Automatic Class III Designation (De Novo) or Humanitarian Device Exemption (HDE) (see Table 2 above). In addition, a thermal spray-coated orthopedic device can be submitted as an Investigational Device Exemption (IDE) device, which allows the device to be used in a clinical study to collect safety and effectiveness data (Ref 13) .
In this article, a submitter or an applicant of a marketing application will also be referred to as ''sponsor,'' as generally referred to by the FDA in their guidance documents. A sponsor of a coated device can apply a plasma spray coating to their own devices (in this case, the sponsor is also the coating company for their device) or contract a third-party coating company to apply the coating. A thirdparty coating company, or a supplier of a thermal spray coating, will be referred to as a ''coating vendor.''
When FDA Review Your Coatings
For an orthopedic device that contains a plasma spray coating, it is important to include the information on the coating materials, manufacturing details, and properties as well as their effects on the final coated device in a marketing application.
If you are a sponsor of a marketing application, and you apply coatings on your device yourself, you can include manufacturing details and testing data of the coating in your marketing application. Alternatively, you can submit this information to the FDA in a Medical Device Master File (MAF). On the other hand, if your coating is applied by a third-party coating company (i.e., a ''coating vendor''), for proprietary reasons, the coating vendor may wish to submit their manufacturing details and testing data for the coating in a master file. In this case, the master file may be referenced by more than one sponsor to support multiple submission types. It should be noted again that the FDA does not clear or approve individual coatings or materials, i.e., a master file on a specific coating will not be reviewed unless it is referenced by a marketing application. Also, coatings and materials are evaluated as part of the final, finished device in the context of the specific device technological characteristics and intended use. If a sponsor of a marketing application is referencing a third party's master file for specific coating information, it is important that the sponsor includes a letter of authorization (LOA) from the coating vendor, which specifies the location of the information relevant to the submission within the master file. The LOA allows the FDA to reference information included within the master file and to discuss concerns applicable to a marketing application with the coating vendor directly as needed. For additional information on master files, please see the FDA website: http://www.fda.gov/MedicalDevices/ DeviceRegulationandGuidance/HowtoMarketYourDevice/ PremarketSubmissions/PremarketApprovalPMA/ucm1427 14.htm (Ref 14) .
Once the FDA receives a marketing application that contains a surface coating, the FDA will review the coating information provided in the submission and/or the referenced master file (if applicable) as part of the review process.
How to Prepare Your Coating Information for FDA Review
To support the addition of a plasma spray coating to your device, it is important to include the following coatingrelated information in a marketing application or a master file for FDA review including:
• Coating description • Coating manufacturing details • Coating properties and characterization data • Effects of coating on coated substrates (implants) • Sterilization and labeling considerations for the coated orthopedic devices
Each of the above items will be further discussed below. As indicated in ''When FDA Review Your Coatings'' section, one option is for coating vendors to provide their proprietary information in a master file.
Coating Description
As a coating is part of the final device, it is important to include an appropriate description of the coating on the device as part of the device description in a marketing application, including, but not necessarily limited to, the following:
1. Coating type and method (e.g., plasma-sprayed Ti coating). 2. Coating thickness (or thickness of each layer if the coating contains multiple layers) and location on the device; e.g., device engineering drawings showing coating thickness and coated portion of the implant. 3. Name of the coating company, master file number, and letter of authorization for the FDA to assess this master file if applicable.
Coating Manufacturing Details
There are some differences in the manufacturing details needed for the different types of marketing applications. Information common to several marketing applications includes a detailed description of raw powder, coating method (e.g., APS), equipment, process steps including any pre-and post-coating processes (e.g., sand blasting and cleaning). 
Coating Properties and Characterization Data
It is important to provide a full characterization of the coating properties including metallurgical (for a Ti coating) or physicochemical (for a HA coating), microstructural, and mechanical properties should be provided. The following sections outline the major resources and general issues for you to consider to appropriately characterize your coating in your marketing application.
FDA Guidance Documents:
The FDA has two current guidance documents for Orthopedic implants with surface coatings, which are intended to assist you in determining the appropriate information and testing to submit in your marketing applications for orthopedic devices that include metallic coatings and/or hydroxyapatite coatings, and are available at the following FDA websites: 
Consensus Standards
The standards organizations (e.g., ISO and ASTM) have developed many materials and testing standards for metallic and HA coatings, some of which are recognized by the FDA. It is recommended that you reference these standards for appropriate testing methods and acceptance criteria (see Subsection 3, below).
As the standards are under continuous revision, for the current edition of the FDA-recognized standards, see the FDA-Recognized Consensus Standards Database website at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfStandards/search.cfm (Ref 19). Tables 3 and 4 summarize the general considerations for characterizing a plasma spray Ti coating and a plasma spray HA coating, respectively, which include the recommended material/coating properties per the current FDA guidance documents, and the associated ISO/ASTM standards for the material/coating specifications and testing methods, as well as special considerations to be noted for porous Ti coatings.
General Recommendations
For a Ti/HA dual coating, in addition to the full characterization of the Ti coating in Table 3 and the physiochemical analysis of the HA coating in Table 4 , it is also important to perform additional microstructural characterization and mechanical testing of the Ti/HA dual coating. If the underlying Ti coating is porous and the coated device is intended to be labeled as porous coated for biological fixation, it is important that a microstructural characterization of the dual coating be conducted to determine if the Ti/HA dual coating still meets the definition of a ''porous coating'' (see Table 3 ).
For each test, it is important to include a complete test report, including a description of the test setup and methods or standards used, a description of the test specimens, a worst-case rationale for the test specimens (e.g., the thickest coating is generally considered the worst case for the mechanical strength testing), pre-specified acceptance criteria, test results including raw data, and test conclusions. Unless a specific test sample (also called a coupon) is described in the test standard, it is important that all characterizations are performed with the final sterilized device from multiple lots, or you may provide a rationale to justify that the test sample is equivalent to the final device in terms of manufacturing process including variability between lots, geometry (e.g., radius of curvature), cleaning and sterilization.
As the thermal spray-coated orthopedic devices are implanted devices, additional cleaning and sterilization are generally needed to minimize infections and related complications. It is also important to evaluate the impact of cleaning, sterilization, and packaging/shelf-life processes on the coating properties to ensure that the coated device is safe for its intended use.
Effects of Coating on Coated Substrates (Implants)
A coating process may affect the physical, chemical (e.g., changes in dimension, color, and chemical structure/stability) or fatigue properties of the coated device; for example, (1) when a coating is significantly thicker than coatings of the same type on legally marketed devices; (2) when a coating process is novel; or (3) when a device material (e.g., polymer) or geometry (e.g., very thin) could be impacted by the coating process. In these situations, it is important that additional tests or a scientific rationale be provided to evaluate the effect of the coating process on properties of the coated device.
Additionally, the Ti and HA coatings on orthopedic devices are patient contacting, which, when used for their intended purpose (i.e., in contact with tissue/bone for a permanent contact duration), may induce a harmful biological response. Therefore, a biocompatibility risk assessment should be conducted and provided per FDA's guidance-Use of International Standard ISO10993-1, ''Biological evaluation of medical devices-Part 1: Evaluation and testing within a risk management process'' (http://www.fda.gov/downloads/medicaldevices/devicer egulationandguidance/guidancedocuments/ucm348890. pdf) (Ref 21) . It is important that the biocompatibility assessment evaluates not only the starting materials used for the coating, but also the subsequent processing of the materials including the coating process and pre-and post-coating processes, cleaning, and sterilization steps, and any residuals from manufacturing aids used during the process.
Sterilization and Labeling Considerations for Coated Devices
Plasma spray Ti and/or HA-coated orthopedic devices are implanted devices, and it is important to adopt adequate sterilization to minimize infections and related complications and label the device appropriately. The following list identifies some common sterilization and labeling issues for marketing applications that contain a plasma spray Ti and/or HA coating. This is not an exhaustive list.
• It is important that plasma spray HA-coated devices be provided sterile using gamma radiation, as other sterilization methods or reprocessing by the end user may affect the integrity of the coating.
• It is important that plasma spray HA-coated joint arthroplasty devices be implanted using a cementless method, and it is clearly specified in the ''Indications for Use Statement'' and labeling, as the HA coating can adversely affect the longevity of cemented fixation.
• A device with a ''porous coating'' (see Table 3 ) may be labeled for biological fixation, but no other enhanced fixation claims have been accepted in labeling for plasma spray Ti and/or HA-coated devices, as the FDA is not currently aware of valid scientific means to assess How FDA Reviews Your Coating in a 510(k) Process?
As discussed in ''When FDA Review Your Coatings'' section, the FDA reviews a plasma spray coating as part of a marketing application and the review starts once the submission is received by the FDA. As indicated in ''Marketing Applications for Medical Devices'' section, most orthopedic medical devices with thermal spray coatings are cleared through the 510(k) process or approved through the PMA process by the FDA prior to commercial distribution in the USA. While these two types of applications follow different review processes and timelines (Ref 22, 23) , the review of the coating information have some similarities. However, for a 510(k) application, the coated device needs to demonstrate substantial equivalence to the identified predicate device; and for a PMA application, which requires additional facilities information and Quality System review (Ref 23), the coated device needs to demonstrate a reasonable assurance of safety and effectiveness. To understand how the coating information is reviewed by the FDA, the review of a traditional 510(k) will be used to illustrate this process with a focus on the review of coating information. The timeline for a traditional 510(k) review is as follows (Fig. 2) : Acceptance Review (also referred as Refuse to Accept or RTA): FDA determines whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review. A 510(k) for a coated device has rarely been placed on RTA hold due to coating issues, so long as minimum coating information is provided.
Substantive Review (SR): FDA conducts substantive review of the 510(k) including coating information provided in both the 510(k) and the referenced master file if applicable, and communicates with submitters via a Substantial Interaction (SI). FDA may contact the 510(k) sponsor for any coating issues identified in the 510(k) and the coating vendor for any issues identified in the master file during this stage through email or telephone.
By the end of the SI stage, if FDA determines that any outstanding deficiencies may be adequately addressed within the timeframe set by the Medical Device User Fee Amendment of 2017 (MDUFA IV) performance goal for a 510(k) (90 FDA days), FDA will choose to continue with Interactive Review (IR). However, if FDA determines that an Additional Information (AI) request is needed, the submission will be placed on AI hold.
Interactive Review (IR): FDA continues interactive communications with the 510(k) sponsor or the coating vendor to resolve any outstanding coating deficiencies. The 510(k) sponsor or the coating vendor should submit any information requested by the FDA to ensure that FDA has a complete response to make the final MDUFA decision by Day 90.
Additional Information (AI): Once the 510(k) is placed on AI hold, the sponsor has 180 calendar days from the date of the AI Request to submit a complete response to the AI Request email. If the 510(k) is being placed on AI hold wholly or partially due to deficiencies identified in the coating master file, for proprietary reasons, the coating vendor will receive a separate email from the FDA listing all deficiencies with the master file. The coating vendor is encouraged to work with the 510(k) sponsor to ensure that a complete response to the master file deficiencies is submitted to the FDA at the same time or before the 510(k) sponsor's AI response and no later than Day 180. Otherwise, the sponsor's AI response will be considered incomplete, and the 510(k) will be deleted after Day 180.
Once the FDA receives the complete AI response including the response from the coating vendor, the clock will restart and the FDA will review the additional information and address any additional issues with the 510(k) sponsor and/or the coating vendor interactively until a final decision is made by Day 90.
Coating vendors can submit their response to deficiencies directly to the FDA through email; however, if they have performed additional testing in response to any major deficiencies, it is ideal if they submit all new or updated testing data as an amendment to their original master files within the requested timeframe and notify the 510(k) applicants that they have submitted the information to the FDA. In this case, all new or updated testing data in the Amendment may also be referenced by more than one sponsor to support multiple submissions as discussed in ''When FDA Review Your Coatings'' section. Additionally, coating vendors can amend their master file with new coating information (e.g., new or updated testing data and new manufacturing information) anytime even if there is no associated 510(k) under FDA review; however, as pointed out in ''When FDA Review Your Coatings'' section, the amended information and data will not be 
